Pegylated interferon alpha is a finite-course, resistance-free choice for selected patients living with chronic viral hepatitis. In October 2025 the national medical-products regulator approved peginterferon alfa-2b combined with nucleos(t)ide analogs for adult chronic hepatitis B patients with sustained HBsAg clearance, the first interferon indication cleared on a clinical-cure endpoint. A hepatitis D antibody approved in January 2026 changed the treatment order there without ending interferon's role, while hepatitis C has mostly moved to interferon-free regimens.
Background: why one drug sits in three different places
Interferon is not a single antiviral drug. It is a class of immune modulators, and how well it works leans heavily on the patient's own immune state. That is why pegylated interferon alpha reads as a retired drug in hepatitis C, a returning first-line choice in hepatitis B, and one of two options in hepatitis D.
Chronic hepatitis C: already off the first line
Direct-acting antivirals made hepatitis C a curable disease. The 2022 national hepatitis C guideline prioritizes interferon-free pan-genotypic regimens, with sustained virologic response above 90 percent across major genotypes, an oral course of 8 to 12 weeks. The old standard, pegylated interferon plus ribavirin, ran for one year with sustained response near 60 percent, only 44 to 53 percent for genotypes 1 and 4, and is contraindicated in decompensated cirrhosis. The national public-health agency's laboratory testing standard puts it plainly: it is no longer used in routine clinical practice.
Clinical conclusion: whenever direct-acting antivirals are available, do not use interferon; return to the old regimen only when no alternative exists, and first exclude decompensated cirrhosis.
Chronic hepatitis B: from backup to first-line contender
Nucleos(t)ide analogs are potent, safe, and easy to take, but most patients need long-term therapy, and annual HBsAg clearance is only about 1 percent. Pegylated interferon complements them: a fixed course, no resistance, and a sustained response after stopping. Three years ago it was still a backup , nucleos(t)ide analogs first (A1), interferon "may be used" (B1), "consider adding" (B2) for favorable groups.
Three documents moved three positions in the past year and a half.
One, October 2025: new indication. Peginterferon alfa-2b won approval for combination with nucleos(t)ide analogs in adult chronic hepatitis B with sustained HBsAg clearance, limited to nucleos(t)ide-analog-treated patients with sustained viral suppression, HBsAg below 1500 IU/ml, and HBeAg negative or below 10 COI. This is the first interferon indication worldwide approved with clinical cure as the endpoint: in the phase III program, 31.4 percent of patients were HBsAg negative with undetectable HBV DNA at week 24 after stopping, and week-130 follow-up showed durability of 100 percent in treatment-naive patients and above 85 percent in treatment-experienced patients.
Two, October 2025: clinical cure consensus. A national expert consensus on functional cure stratified patients by baseline HBsAg into three tiers, giving "who can inject" an operable standard.
Three, April 2026: a regional liver-society guideline. It listed pegylated interferon alpha as a first-line or add-on regimen (A1) for the first time and proposed a "total cure" strategy: start treatment whenever HBV DNA is detectable and alanine aminotransferase is not below 40 U per L.
But the domestic prevention and treatment guideline has not been revised. The 2022 edition is still current, and its "nucleos(t)ide analogs first (A1)" wording stands. Prescription reality: the label and international guidelines have moved a step ahead, while the domestic guideline stays put. Writing "consistent with the label indications" in the chart is more defensible than a generic "guideline recommendation."
Pegylated interferon alpha in chronic hepatitis B: three treatment scenarios
Distinguishing scenarios matters more than memorizing doses , entry criteria and stopping points differ across the three.
Scenario A: initial monotherapy (recommendations 14 and 16)
For patients with an antiviral indication, no prior nucleos(t)ide analog use, and a wish for a finite course, such as a pregnancy plan after stopping. HBeAg-positive patients are assessed at week 24, HBeAg-negative patients at week 12; effective patients continue for 48 weeks, extendable to 96 weeks within the limit (B1), ineffective patients stop and switch to nucleos(t)ide analogs. The item most easily confused: HBeAg-positive patients are judged at week 24, negative patients at week 12; the former requires "both indicators fail" to stop, the latter "either indicator fails" to stop. Write it into the follow-up template instead of relying on memory.
Scenario B: add-on for nucleos(t)ide-analog-treated favorable patients (the most changed group)
This is where the 2025 change hit hardest. The 2022 guideline required three things at once: HBV DNA below the detection limit, HBeAg seroconversion, and HBsAg below 1500 IU/ml; add-on could then be considered based on patient willingness (B2). There is one decision node , week 24: HBsAg below 200 IU/ml or a decline over 1 log means continuing to 48 to 96 weeks; otherwise stop interferon and keep nucleos(t)ide analogs.
The October 2025 label wrote this group into the indications with more specific conditions: nucleos(t)ide-analog-treated, sustained virologic suppression, HBsAg below 1500 IU/ml, HBeAg negative or below 10 COI. The difference: the label also covers HBeAg-positive patients below 10 COI, while the guideline text says HBeAg seroconversion. For these edge patients, the label wording is more defensible.
Two operational details: first, "add" never means "switch" , nucleos(t)ide analogs are never stopped. Second, lower baseline means higher success: a real-world cohort study showed clearance up to 53.6 percent when baseline HBsAg is below 100 IU/ml; for older patients at 1000 to 1500 IU/ml, set expectations first.
Scenario C: compensated and decompensated cirrhosis (recommendations 18 and 19)
Compensated cirrhosis (A1): entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide is first-line long-term treatment; if pegylated interferon is used, adverse effects need close monitoring. The text says "if," not "recommend" , an exception requiring strong justification and tight monitoring.
Decompensated cirrhosis (A1): pegylated interferon is contraindicated, no exception. Pregnancy or a short-term pregnancy plan is an absolute contraindication; children need specialist assessment, and some formulations are not recommended below age 18.
Three tiers by baseline HBsAg
Optimal (below 500 IU/ml): the highest possibility of cure.
Favorable (500 to 1500 IU/ml, or postpartum women): important beneficiaries of the cure strategy.
Cultivate (above 1500 IU/ml): use nucleos(t)ide analogs first to lower the load, then discuss conversion; uncured patients can be retreated intermittently.
Scenario | Entry criteria | Regimen | Stopping point |
A1 initial, HBeAg-positive | Antiviral indication, no prior nucleos(t)ide analog; HBV DNA below 2 x 10^8 IU/ml, ALT 2 to 10 times the upper limit of normal, genotypes A or B respond better | Monotherapy 48 weeks, extendable to 96 weeks | Week 24: DNA decline below 2 log10 and HBsAg above 2 x 10^4 IU/ml |
A2 initial, HBeAg-negative | Same as above; no reliable efficacy predictor, earlier judgment needed | Monotherapy 48 weeks | Week 12: DNA decline below 2 log10 or HBsAg decline below 1 log10 |
B nucleos(t)ide-analog-treated favorable patients | DNA below detection limit, HBsAg below 1500 IU/ml; HBeAg seroconversion (label: negative or below 10 COI) | Nucleos(t)ide analogs continue, add-on 48 to 96 weeks | Week 24: HBsAg not below 200 IU/ml and decline below 1 log |
C compensated cirrhosis | Compensated liver function, no portal-hypertension complications | Nucleos(t)ide analogs first-line; interferon only with close monitoring | Stop immediately on decompensation signs |
Dose, formulation, and course: peginterferon alfa-2b fixed 180 micrograms weekly
Three interferon products are available domestically, and their dose units differ completely , this is the easiest place to write a wrong prescription.
Product | Adult dose | Frequency | Notes |
Peginterferon alfa-2a | 180 micrograms, subcutaneous injection | Once weekly | Stable blood concentration; guideline-recommended formulation |
Peginterferon alfa-2b | 180 micrograms, subcutaneous injection (48-week course for hepatitis B) | Once weekly | Fixed dose, not adjusted by body weight |
Conventional interferon alpha | 3 to 5 million IU (alfa-1b 30 to 50 micrograms) | Every other day or 3 times weekly | Large concentration swings; not the first choice |
One common dose trap: do not apply the hepatitis C weight-based rule to hepatitis B. Peginterferon alfa-2b for chronic hepatitis B is a fixed 180 micrograms once weekly; the 1.0 to 1.5 micrograms-per-kilogram rule would give a 60-kilogram person only 80 to 100 micrograms , an underdose.
Inject into abdominal or thigh subcutaneous tissue, on the same weekday every week, refrigerate at 2 to 8 degrees Celsius and do not freeze. A missed injection does not call for a double dose; continue on the original schedule. The course baseline is 48 weeks, extendable to 96 weeks for partial responders (B1); conventional interferon runs 4 to 6 months and is not the first choice when pegylated interferon is available.
Time point | What to do |
Week 0 | Baseline assessment: blood count, liver and kidney function, thyroid, quantitative HBsAg |
Week 12 | First judgment for HBeAg-negative patients: HBV DNA and HBsAg decline |
Week 24 | Judgment for HBeAg-positive and add-on patients: is HBsAg below 200 IU/ml? |
Week 48 | Standard course endpoint: assess efficacy and sustained response |
Week 96 | Course upper limit: do not extend further |
D-standard: continue to 48 weeks, then follow up every 3 to 6 months after stopping. Partial response: extend to 96 weeks , extension is not indefinite use. Failure: stop and switch to nucleos(t)ide analogs , continuing only prolongs exposure without adding benefit.
Three red lines, plus two endpoints
Interferon benefit is all-or-nothing. Continuing to 48 weeks for a patient already unlikely to respond at week 24 only prolongs exposure, not benefit. The guidelines write stopping into recommendations with evidence grades precisely to block the "try a bit longer" impulse.
Red line one (week 12, HBeAg-negative initial treatment): HBV DNA decline below 2 log10 IU/ml, or HBsAg decline below 1 log10 IU/ml , stop pegylated interferon and switch to nucleos(t)ide analogs.
Red line two (week 24, HBeAg-positive initial treatment): HBV DNA decline below 2 log10 IU/ml and HBsAg still above 2 x 10^4 IU/ml , stop pegylated interferon and switch to nucleos(t)ide analogs.
Red line three (week 24, nucleos(t)ide-analog add-on): HBsAg not below 200 IU/ml , stop pegylated interferon and keep nucleos(t)ide analogs.
Reverse reminder: inside the red lines, do not reduce or stop lightly. A patient whose HBsAg has fallen to 180 IU/ml by week 24 should continue to 48 weeks and extend to 96 when indicated , the benefit is real. Stopping early throws away a response within reach. Stop by indicators, not by emotion.
Distinguish the two endpoints. The treatment endpoint is week 48; the cure endpoint is week 24 after stopping: HBsAg below 0.05 IU/ml, HBV DNA undetectable, and normal liver function , all three together count as clinical cure. The 31.4 percent figure belongs to this timepoint. So finishing 48 weeks neither declares a result nor justifies stopping nucleos(t)ide analogs right away: consolidate first per the consensus, then discuss stopping, and keep liver-cancer surveillance during consolidation and after stopping.
Population and node | Judgment condition | Action |
HBeAg-negative initial, week 12 | HBV DNA decline below 2 log10, or HBsAg decline below 1 log10 | Stop, switch to nucleos(t)ide analogs (B1) |
HBeAg-positive initial, week 24 | HBV DNA decline below 2 log10, and HBsAg still above 20,000 IU/ml | Stop, switch to nucleos(t)ide analogs (A1) |
Nucleos(t)ide-analog add-on, week 24 | HBsAg not below 200 IU/ml and decline below 1 log | Stop interferon, keep nucleos(t)ide analogs (B2) |
HBeAg-negative initial, week 12 on target | HBsAg below 200 IU/ml or decline over 1 log | Continue to 48 to 96 weeks (B1) |
Who should not inject: absolute and relative contraindications
Category | Specific situations |
Absolute contraindications | Pregnancy or a short-term pregnancy plan; psychiatric history; uncontrolled epilepsy; decompensated cirrhosis; uncontrolled autoimmune disease; severe infection, retinal disease, heart failure, chronic obstructive pulmonary disease |
Relative contraindications | Thyroid disease; past depression; uncontrolled diabetes, hypertension, heart disease; neutrophils below 1.0 x 10^9 per liter and/or platelets below 50 x 10^9 per liter; total bilirubin above 51 micromoles per liter |
Relative contraindications do not mean never: first control controllable factors, tighten monitoring, and discuss risk versus benefit clearly. Thyroid-antibody positive with normal thyroid function can start, with thyroid monitoring moved up to every 8 to 12 weeks.
Five things to complete before prescribing
- Blood count, liver function, kidney function, thyroid function plus thyroid autoantibodies.
- Quantitative HBsAg, HBeAg and anti-HBe, high-sensitivity HBV DNA; add anti-HDV and HDV RNA when hepatitis D is suspected.
- Liver stiffness or imaging to exclude decompensation: albumin, bilirubin, prothrombin time, platelets, ascites, varices.
- Mental-health assessment: past depression and family history; PHQ-9 for rapid screening.
- Fundoscopy for diabetes or retinal-disease risk; pregnancy test and contraception for women of childbearing age.
Side effects and monitoring cadence
Most interferon adverse effects are controllable, provided they are disclosed early, monitored regularly, and handled by threshold. Flu-like symptoms after the first injection often break adherence within two weeks if the patient was not warned.
Adverse effect | Threshold and action | Notes |
Flu-like symptoms | Paracetamol or ibuprofen 30 minutes before or at injection | Appears 2 to 4 hours after injection, eases within 48 hours, lessens with each dose |
Marrow suppression | Reduce dose at neutrophils no higher than 0.75 x 10^9 per liter or platelets below 50 x 10^9 per liter, recheck in 1 to 2 weeks; hold at 0.5 x 10^9 per liter or platelets below 25 x 10^9 per liter; granulocyte colony-stimulating factor is an option for marked neutrophil decline | Dose reduction is not stopping; most patients return to the original dose and finish the course |
Thyroid dysfunction | Mild cases: observe or treat symptomatically; severe cases: stop and consult endocrinology, follow up for 6 months after ending | Thyroid-stimulating hormone every 12 weeks; earlier if antibodies are positive |
Psychiatric events | Depression, delusion, severe anxiety: stop immediately, psychiatry consult when needed | The only class that does not start with dose reduction and observation |
Autoimmune disease | Antibody positivity alone does not necessarily require stopping; clinical thyroid disease, diabetes, thrombocytopenia, psoriasis, or lupus-like syndrome needs specialist consultation, stop if severe | Distinguish antibody positivity from clinical illness |
Rare but stop immediately | Retinal disease, interstitial pneumonitis, hearing loss, kidney injury, cardiovascular events | Actively ask about new blurred vision, dry cough with shortness of breath |
Monitoring rhythm: blood counts every 1 to 2 weeks in the first month, then every 2 to 4 weeks; thyroid-stimulating hormone and liver function every 12 weeks; HBsAg and HBV DNA at weeks 12, 24, and 48; after stopping, follow up every 3 to 6 months for at least 12 months, with the week-24 post-stop visit judging cure.
Three case reviews
The one to add. A 34-year-old man, HBeAg-negative, on entecavir for 4 years, HBV DNA undetectable, HBsAg 780 IU/ml, normal thyroid function, liver stiffness 5.8 kilopascals. All four conditions met: add peginterferon alfa-2b 180 micrograms once weekly, keep nucleos(t)ide analogs. HBsAg fell to 180 IU/ml at week 24, continue; HBsAg negative with anti-HBs at week 72, consolidate; HBsAg still below 0.05 IU/ml at week 24 after stopping , clinical cure. Baseline 780 IU/ml sits near the front of the favorable tier. Say "cure" only after week 24 off treatment.
The one to stop. A 41-year-old woman, HBeAg-positive initial treatment, chose monotherapy for a finite course. Baseline HBV DNA 3.2 x 10^7 IU/ml, ALT 3 times the upper limit of normal, HBsAg 28,000 IU/ml. Week 24: DNA down only 1.2 log, HBsAg 22,000 IU/ml , both conditions met , stop per recommendation 14 and switch to tenofovir alafenamide; DNA undetectable within 6 months. Review: 24 more weeks would only add symptom burden. Stopping here is not failure; it is stopping loss by the rules.
The one not to start. A 52-year-old man with hepatitis B cirrhosis, albumin 31 grams per liter, total bilirubin 42 micromoles per liter, small ascites (Child-Pugh B), asking for interferon because HBsAg was only 300 IU/ml. This is already decompensated: recommendation 19 clearly contraindicates interferon, which can trigger a hepatitis flare or even liver failure. Switch to tenofovir disoproxil fumarate long-term and reassess after ascites is controlled. Review: low HBsAg is easy to look at in isolation. Lower is better to treat, but only when liver function is compensated.
Five common misconceptions
One: interferon was upgraded, so low HBsAg means you can inject. Both parts are wrong. The upgrade widened the indication for specific groups, not the eligibility boundary , HBsAg below 1500 IU/ml, DNA suppressed, compensated liver function, normal thyroid and psychiatric screening, and no absolute contraindication; miss one condition and there is no injection.
Two: once started, you cannot stop. The opposite: interferon's core advantage is explicit stop points at weeks 12, 24, 48, and 96.
Three: hepatitis C can still take interferon. Not when direct-acting antivirals are available: the old regimen reaches sustained response near 60 percent over a year, while pan-genotypic direct-acting antivirals exceed 90 percent in 8 to 12 weeks.
Four: hepatitis D has only interferon. Not since 2026: libevitug was conditionally approved, with 48-week combination response of 44.1 percent , but it requires intravenous infusion.
Five: side effects just need enduring. Marrow suppression has clear reduction and hold thresholds; psychiatric symptoms mean stop on sight; retinal disease and interstitial pneumonitis are immediate-stop events.
Bottom line
Pegylated interferon alpha is a finite-course, immune-based option for selected chronic hepatitis B and D patients , not a lifelong drug, and not a universal one. Check HBsAg level, liver compensation, HBeAg status, and red-line indicators before starting; stop by the numbers, not by feeling; and remember that clinical cure can only be named 24 weeks after the last injection.
FAQ
What is pegylated interferon alpha and how does it differ from nucleos(t)ide analogs?
Pegylated interferon alpha is an immune modulator given by subcutaneous injection, usually once weekly for a fixed 48-week course. Nucleos(t)ide analogs are oral antivirals that directly suppress viral replication and are often taken long term. Interferon has no resistance and can produce a sustained response after stopping, while nucleos(t)ide analogs rarely clear HBsAg on their own, with annual clearance around 1 percent. The two are complementary rather than interchangeable, and in hepatitis B add-on therapy the nucleos(t)ide analog is never stopped.
Who qualifies for peginterferon alfa-2b add-on therapy in chronic hepatitis B?
Adults with chronic hepatitis B who are already on nucleos(t)ide analogs, with sustained virologic suppression, HBsAg below 1500 IU/ml, and HBeAg negative or below 10 COI. The October 2025 label also covers HBeAg-positive patients below 10 COI, a group the older guideline wording did not clearly include. Patients must have compensated liver function and pass thyroid, psychiatric, and blood-count screening before starting.
When should pegylated interferon alpha be stopped under the three red lines?
Stop and switch to nucleos(t)ide analogs if, at week 12 for HBeAg-negative initial treatment, HBV DNA falls less than 2 log10 or HBsAg falls less than 1 log10; or at week 24 for HBeAg-positive initial treatment, DNA falls less than 2 log10 and HBsAg stays above 2 x 10^4 IU/ml; or at week 24 for nucleos(t)ide-analog add-on, HBsAg stays at or above 200 IU/ml. Patients inside the red lines should not be stopped early based on feeling.
Is pegylated interferon alpha still used for hepatitis C?
No, not when direct-acting antivirals are available. Interferon-free pan-genotypic regimens reach sustained virologic response above 90 percent in 8 to 12 weeks, all oral. The old pegylated interferon plus ribavirin course ran for one year with sustained response near 60 percent and is not suitable for decompensated cirrhosis. National public-health guidance states it is no longer used in routine clinical practice.
What changed for hepatitis D in January 2026?
On January 23, 2026, the national medical-products regulator conditionally approved libevitug, the first monoclonal antibody for adult chronic hepatitis D including compensated cirrhosis. It targets the viral PreS1 region and blocks hepatitis B and D entry into liver cells, with 48-week combination response of 44.1 percent and virologic response of 60 percent. Bulevirtide remains unapproved domestically. Interferon has not exited: it is injected subcutaneously, covered by reimbursement, and usable at primary-level facilities, so the sequence changed , confirm hepatitis D RNA first, then choose between mechanisms.
What is the fixed dose of peginterferon alfa-2b for chronic hepatitis B?
For chronic hepatitis B, peginterferon alfa-2b is a fixed 180 micrograms injected under the skin once weekly for a 48-week course, not adjusted by body weight. Do not apply the hepatitis C weight-based rule of 1.0 to 1.5 micrograms per kilogram: for a 60-kilogram person that yields only 80 to 100 micrograms, an underdose. Inject in the abdomen or thigh on a fixed weekday, refrigerate at 2 to 8 degrees Celsius, and never freeze. A missed injection is not made up with a double dose.
Which patients must never receive pegylated interferon alpha?
Absolute contraindications include pregnancy or a short-term pregnancy plan, psychiatric history, uncontrolled epilepsy, decompensated cirrhosis, uncontrolled autoimmune disease, severe infection, retinal disease, heart failure, and chronic obstructive pulmonary disease. A patient with Child-Pugh B cirrhosis and ascites, for example, must not start interferon even with a low HBsAg level, because the drug can trigger a hepatitis flare or liver failure.
How are flu-like symptoms and blood-count changes managed during treatment?
Flu-like symptoms often appear two to four hours after injection and ease within 48 hours; paracetamol or ibuprofen taken 30 minutes before or at injection helps, and symptoms lessen with each dose. For blood counts, reduce the dose when neutrophils fall to 0.75 x 10^9 per liter or platelets below 50 x 10^9 per liter, and hold the drug at 0.5 x 10^9 per liter or platelets below 25 x 10^9 per liter. Most patients return to the original dose and complete the course.
How is clinical cure defined after stopping treatment?
Clinical cure is judged at week 24 after the last injection, not at week 48 of treatment. All three conditions must hold at the same time: HBsAg below 0.05 IU/ml, HBV DNA undetectable, and normal liver function. In the phase III program, 31.4 percent of patients met this off-treatment definition at week 24, with durability shown at week 130 follow-up. Nucleos(t)ide analogs should not be stopped immediately at week 48; consolidation comes first.
Can pegylated interferon alpha be used in decompensated cirrhosis?
No. Decompensated cirrhosis is an absolute contraindication with no exception. Compensated cirrhosis is an exception-only setting: guidelines list nucleos(t)ide analogs as first-line long-term treatment, and interferon may be used only with strong justification and close adverse-effect monitoring. Before any prescription, confirm the absence of decompensation signs such as ascites, varices, low albumin, high bilirubin, and prolonged prothrombin time.
What monitoring is required during and after interferon treatment?
In the first month, check blood counts every one to two weeks, then every two to four weeks; check thyroid-stimulating hormone and liver function every 12 weeks; measure HBsAg and HBV DNA at weeks 12, 24, and 48. After stopping, follow up every three to six months for at least 12 months, and the week-24 post-stop visit decides whether clinical cure has been reached. Liver cancer surveillance continues during consolidation and after stopping.
What are the most common misunderstandings about interferon therapy?
Patients often think low HBsAg alone qualifies them for interferon after an upgrade, but the upgrade widened the indication for specific groups, not the eligibility boundary. They also think interferon cannot be stopped, while its core advantage is explicit stop points at weeks 12, 24, 48, and 96. Others believe hepatitis C still uses interferon, or that hepatitis D has no other option , both outdated since 2025 and 2026. Side effects should be managed by thresholds, not endured.